Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hormone protocol could make IVF cheaper and easier for women with low egg supply

NCT ID NCT05847283

Disease control Sponsor: Tam Anh TP. Ho Chi Minh General Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether using the hormone dydrogesterone (taken as a pill) alongside standard fertility injections can help women with low ovarian reserve collect more eggs for IVF. The trial compares this approach to the usual GnRH antagonist protocol. Researchers will track pregnancy rates after the first embryo transfer in 730 women aged 18-37.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Dydrogesterone (oral hormone) and human menopausal gonadotrophin (hMG) injections
What this could lead to
If successful, this could offer a more affordable and patient-friendly way to collect eggs for IVF in women with low ovarian reserve, potentially improving pregnancy chances.
What could go wrong
This is a Phase 2/3 trial with 730 participants, but results may not apply to all women. The protocol may not significantly improve egg quality or pregnancy rates, and side effects from hormones are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 730 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2023

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 37 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Woman aged between 18 and 37 years * AFC ≤ 5 and/or AMH ≤ 1.2 ng/ml * Agree to perform freeze-all strategy and single frozen blastocyst embryo transfer Exclusion Criteria: * Oocyte recipient * Indication of preimplantation genetic testing * Known allergic reactions to medications in the Study (progesterone products, GnRH antagonist….) * Basal FSH above 15mIU/mL. * Have contraindications of ART treatment (e.g. critical or acute diseases) * Retrieved sperm * Repeated Implantation failure ( ≥ 3 failed embryo transfers with good-quality embryos) * Inability to comply with the study procedures. * Patients with a history of thyroid cancer who are on hormone replacement therapy or those diagnosed with thyroid diseases at the time of eligibility assessment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diminished ovarian reserve are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ovarian dysfunction primary ovarian failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diminished ovarian reserve

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • IVFTA

    RECRUITING

    Hanoi, Hanoi, 100000, Vietnam

  • Ivfta Hcmc

    RECRUITING

    Ho Chi Minh City, Ho Chi Minh, 70000, Vietnam

More trials for these conditions

Other studies related to the condition(s) this trial covers.